Q-omics provides the consensus-scored KRT24 profile across patient tissues and cancer cell-line models. KRT24 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KRT24 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KRT24 RNA expression shows 7,614 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where KRT24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT24 survival associations across molecular data types. KRT24 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT24 RNA expression–survival associations across cancer types. High KRT24 expression shows unfavorable associations in ACC, KIRP, DLBC and BLCA, but favorable associations in LUAD and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KRT24 RNA expression.
This table summarizes KRT24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT24 shows lower tumor expression in KIRC, COAD, BLCA, KICH, READ and HNSC. The KIRC box plot shows higher KRT24 RNA expression in normal versus tumor tissue (log2 FC = −0.247, t-test p < 0.001).
This table shows molecular features associated with KRT24 in patient tissues and cancer cell lines. In patient samples, KRT24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BREAST.
